Taken together, the preclinical studies proved that PF-3758309 is a potent druglike PAK4 inhibitor suitable for clinical trials for treating colon, leukemia, and pancreatic cancers with potentials to improve immune microenvironment. Here, PAK4 is linked to familial pancreatic carcinoma.